

# Josuel Ora

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2335912/publications.pdf>

Version: 2024-02-01

93  
papers

2,357  
citations

257101

24  
h-index

223531

46  
g-index

94  
all docs

94  
docs citations

94  
times ranked

2749  
citing authors

#	ARTICLE	IF	CITATIONS
1	Common Mechanisms of Dyspnea in Chronic Interstitial and Obstructive Lung Disorders. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 299-309.	2.5	196
2	Mechanisms of activity-related dyspnea in pulmonary diseases. <i>Respiratory Physiology and Neurobiology</i> , 2009, 167, 116-132.	0.7	180
3	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 11-16.	2.0	159
4	Evolution of Dyspnea during Exercise in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1367-1373.	2.5	140
5	Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , 2017, 124, 6-14.	1.3	131
6	Combined Effects of Obesity and Chronic Obstructive Pulmonary Disease on Dyspnea and Exercise Tolerance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 964-971.	2.5	122
7	Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. <i>Thorax</i> , 2009, 64, 216-223.	2.7	88
8	Effect of obesity on respiratory mechanics during rest and exercise in COPD. <i>Journal of Applied Physiology</i> , 2011, 111, 10-19.	1.2	74
9	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016, 17, 70.	1.4	71
10	Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , 2017, 129, 117-123.	1.3	64
11	Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 15-27.	1.1	57
12	Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. <i>European Journal of Applied Physiology</i> , 2009, 107, 633-643.	1.2	55
13	Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , 2015, 109, 1305-1311.	1.3	54
14	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , 2017, 129, 189-198.	1.3	54
15	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. <i>BMC Pulmonary Medicine</i> , 2018, 18, 70.	0.8	53
16	Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , 2016, Volume 11, 3007-3013.	0.9	52
17	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , 2017, 26, 160043.	3.0	50
18	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000625.	3.1	46

#	ARTICLE	IF	CITATIONS
19	Effects of Obesity on Perceptual and Mechanical Responses to Bronchoconstriction in Asthma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 125-133.	2.5	43
20	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of COPD, 2017, Volume 12, 3469-3485.	0.9	35
21	Guidance on nebulization during the current COVID-19 pandemic. Respiratory Medicine, 2021, 176, 106236.	1.3	35
22	Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. COPD Research and Practice, 2015, 1, .	0.7	33
23	Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. European Journal of Pharmacology, 2015, 761, 383-390.	1.7	31
24	Role of muscarinic antagonists in asthma therapy. Expert Review of Respiratory Medicine, 2017, 11, 239-253.	1.0	27
25	Does bronchoscopy help the diagnosis in COVID-19 infection?. European Respiratory Journal, 2020, 56, 2001619.	3.1	27
26	Respiratory and leg muscles perceived exertion during exercise at altitude. Respiratory Physiology and Neurobiology, 2011, 177, 162-168.	0.7	25
27	Does exercise test modality influence dyspnoea perception in obese patients with COPD?. European Respiratory Journal, 2014, 43, 1621-1630.	3.1	24
28	Advances with glucocorticoids in the treatment of asthma: state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 2305-2316.	0.9	23
29	Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. Current Opinion in Pulmonary Medicine, 2010, 16, 144-149.	1.2	21
30	Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. Current Opinion in Pharmacology, 2018, 40, 34-38.	1.7	20
31	Treatable Mechanisms in Asthma. Molecular Diagnosis and Therapy, 2021, 25, 111-121.	1.6	17
32	New Avenues for Phosphodiesterase Inhibitors in Asthma. Journal of Experimental Pharmacology, 2021, Volume 13, 291-302.	1.5	17
33	Sex differences in COPD management. Expert Review of Clinical Pharmacology, 2021, 14, 323-332.	1.3	16
34	Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung, 2021, 199, 335-343.	1.4	16
35	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Molecular Diagnosis and Therapy, 2019, 23, 603-614.	1.6	15
36	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. Expert Review of Respiratory Medicine, 2018, 12, 43-54.	1.0	14

#	ARTICLE	IF	CITATIONS
37	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety, 2018, 17, 589-596.	1.0	13
38	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2019, 20, 737-750.	0.9	13
39	A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. Respiratory Medicine, 2013, 107, 2014-2021.	1.3	12
40	&lt;p&gt;Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease&lt;/p&gt;. Journal of Experimental Pharmacology, 2020, Volume 12, 559-574.	1.5	12
41	Autonomic system modification in zen practitioners. Indian Journal of Medical Sciences, 2013, 67, 161.	0.1	11
42	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. Pulmonary Pharmacology and Therapeutics, 2017, 44, 83-87.	1.1	11
43	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. Journal of Affective Disorders, 2021, 278, 339-340.	2.0	11
44	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respiratory Medicine, 2013, 107, 107-111.	1.3	10
45	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2015, 8, 529-539.	1.3	10
46	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine, 2019, 14, 25.	0.6	10
47	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics: Targets and Therapy, 2021, Volume 15, 363-374.	3.0	10
48	Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. Monaldi Archives for Chest Disease, 2022, , .	0.3	10
49	Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2016, 17, 977-988.	0.9	9
50	Happy hypoxemia, or blunted ventilation?. Respiratory Research, 2021, 22, 4.	1.4	9
51	Step-up and step-down approaches in the treatment of asthma. Expert Review of Respiratory Medicine, 2021, 15, 1159-1168.	1.0	9
52	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. BioMed Research International, 2016, 2016, 1-7.	0.9	8
53	The future of inhalation therapy in chronic obstructive pulmonary disease. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100092.	1.7	8
54	Estimation of the exercise ventilatory compensation point by the analysis of the relationship between minute ventilation and heart rate. European Journal of Applied Physiology, 2008, 104, 87-94.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Differential pharmacology and clinical utility of long-acting bronchodilators in COPD &ndash; focus on olodaterol. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1805.	0.9	7
56	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 791-793.	2.0	7
57	Onset of action of budesonide/formoterol SpiromaxÂ® compared with budesonide/formoterol TurbuhalerÂ® in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 39, 48-53.	1.1	7
58	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 891-906.	2.4	7
59	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to bedside study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102050.	1.1	7
60	Dual bronchodilation and exacerbations of COPD. <i>Journal of Thoracic Disease</i> , 2016, 8, 2383-2386.	0.6	6
61	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. <i>Neurological Sciences</i> , 2020, 41, 2671-2674.	0.9	6
62	Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. <i>Respiratory Medicine</i> , 2014, 108, 307-313.	1.3	5
63	Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2043-2053.	0.9	5
64	Olodaterol for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 861-866.	1.9	4
65	Management of COPD patients during COVID: difficulties and experiences. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1025-1033.	1.0	4
66	Pulmonary Rehabilitation in Noncystic Fibrosis Bronchiectasis. <i>Respiration</i> , 2022, 101, 97-105.	1.2	4
67	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 917-927.	0.9	4
68	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	3
69	Dog allergen immunotherapy and allergy to furry animals. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 590.	0.5	2
70	Indacaterol/Glycopyrronium Combination for COPD. <i>Pulmonary Therapy</i> , 2017, 3, 45-57.	1.1	2
71	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 20-26.	1.1	2
72	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis. , 2020, , .		2

#	ARTICLE	IF	CITATIONS
73	Gastroesophageal reflux and <scp>COPD</scp> exacerbations: Is cholinergicâ€mediated oesophagoâ€bronchial reflex a possible link?. <i>Respirology</i> , 2016, 21, 1496-1497.	1.3	1
74	Current long-acting muscarinic antagonists for the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-15.	0.9	1
75	Clinical synergism of LABA/LAMA combinations in COPD patients. , 2017, , .		1
76	Analysis of exhaled air for a rapid, sensible and specific diagnosis of COPD. , 2015, , .		1
77	Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits. , 2020, , 66-81.		1
78	A case of pancytopenia and splenomegaly: haematological disease?. <i>Internal and Emergency Medicine</i> , 2007, 2, 238-242.	1.0	0
79	Effects Of Dead Space Loading On The Intensity, Quality And Unpleasantness Of Perceived Respiratory Discomfort During Incremental Cycle Exercise In The Healthy Elderly. , 2010, , .		0
80	A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF. , 2015, , .		0
81	Searching for synergistic interaction between acclidinium (ACL) and formoterol (FOR): From bench to bedside. , 2015, , .		0
82	Onset of action of acclidinium (ACL), glycopyrronium (GLY) and tiotropium (TIO): A comparison in COPD patients. , 2015, , .		0
83	Qualitative aspects of exertional dyspnea in ILD patients before and after oxygen supplementation. , 2015, , .		0
84	Comparative evaluation on the synergism of roflumilast (RFL) and glycopyrronium (Gly) vs ciclesonide (<i>CLS</i>) and Gly on lung volumes and exercise tolerance in severe COPD. , 2015, , .		0
85	Onset of action of formoterol/budesonide (F/B) SpiromaxÂ® compared with F/B TurbuhalerÂ® in patients with COPD: A preliminary report. , 2016, , .		0
86	Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an<i>ex vivo</i> model of COPD exacerbation. , 2016, , .		0
87	Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone. , 2016, , .		0
88	LABA/LAMA combination, exercise and lung hyperinflation in COPD: a meta-analysis. , 2017, , .		0
89	Synergistic interaction between beclomethasone dipropionate and formoterol fumarate in an ex vivo model of bronchial asthma. , 2018, , .		0
90	Bidimensional comparative analysis of LABA/LAMA FDCs in COPD. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	Once- vs. twice-daily inhaled therapy in asthma: a network meta-analysis. , 2019, , .		0
92	Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients. , 2020, , .		0
93	A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology, 2022, 15, 269-283.	1.3	0